CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
1,327
1,327
29,575
7,894
2,173
Cost of revenue
204
204
-
-
-
Gross profit
1,123
1,123
-
-
-
Operating expenses
Research development
19,630
19,630
18,537
15,073
15,658
Selling general and administrative
11,770
11,770
11,665
10,756
16,819
Total operating expenses
31,400
31,400
30,202
25,829
32,477
Operating income or loss
-30,277
-30,277
-627
-17,935
-30,304
Interest expense
3,339
3,339
-
-
-
Total other income/expenses net
669
669
1,003
-275
-466
Income before tax
-32,947
-32,947
376
-18,210
-30,770
Income from continuing operations
-32,947
-32,947
376
-18,210
-30,770
Net income
-32,947
-32,947
376
-18,210
-30,770
Net income available to common shareholders
-32,947
-32,947
376
-18,210
-30,770
Basic EPS
-
-
0.01
-0.39
-0.81
Diluted EPS
-
-
0.01
-0.39
-0.81
Basic average shares
-
-
58,492
46,507
38,171
Diluted average shares
-
-
59,907
46,507
38,171
EBITDA
-
-29,608
-449
-17,935
-30,304